Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients with Novel coronavirus pneumonia diagnosed according to ; (2) Inpatients aged >18 years old; (3) Patients Know the informed consent, voluntary participate in this clinical trial and sign informed consent.
Exclusion criteria
Exclusion criteria: (1) Death is expected within 48 hours; (2) Basic diseases such as primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation , congenital heart disease, gastroesophageal reflux disease, congenital pulmonary airway malformation and more with the exact evidence of bacterial infection; (3) Patients with the following conditions: Daily treatment of asthma, chronic respiratory disease, bacterial infections of the respiratory system such as suppurative tonsillitis, acute tracheal bronchitis, sinusitis, otitis media, etc that affect clinical trial evaluation. Chest CT confirmed the existence of severe pulmonary interstitial lesions, bronchiectasis and other basic pulmonary diseases; (4) As judged by the researcher, past or present diseases may affect the participation of patients in the research outcome, including malignant diseases, autoimmune diseases, severe malnutrition, liver and kidney diseases, hematological diseases, nervous system diseases, endocrine diseases and serious diseases affecting the immune system such as human immunodeficiency virus (HIV) infection, or blood system, or splenectomy, organ transplantation, etc. (5) Mental state unable to cooperation: suffering from mental illness, unabling to control or express clearly; (6) Allergic constitution (such as allergic to two or more drugs or food) or history of alleric to this product and conventional treatment drugs; (7) History of substance abuse or dependence; (8) Pregnant or nursing women; (9) Participants in clinical trials of other drugs in the past 3 months; (10) Researchers believe that patients are not suitable for any other situation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary symptom remission rate;Chest CT;Incidence of deterioration;The defervescence time;The time for the positive nucleic acid of the novel coronavirus to turn negative; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood lipid;Renal function;The myocardial enzymes;C-reactive protein;T-lymphocyte subsets;Blood glucose;Blood gas analysis;Liver function test;Serum procalcitonin;Urine test;Haematological;Coagulation function test;Interleukin; | — |
Countries
China
Contacts
Public ContactJing-Guo Cheng
WenZhou Medical University
Outcome results
None listed